Genmab’s 25th Anniversary

From Where We Started to Where We are Going​

February 25 marks Genmab’s 25th anniversary.

Over the past quarter-century, Genmab has emerged as a scientific leader in antibody research, working towards the goal of pioneering and revolutionizing the way we treat cancer and other serious diseases.

Since our founding in 1999, innovative science has been our core, as we strive to create medicines that have never been made before for patients with limited treatment options facing cancer and other serious diseases.

Today, our innovations power eight approved antibody-based medicines and our workforce has grown from 10 to 2,100+ people internationally.​

Genmab’s 25th Anniversary

Powered by our extra[not]ordinaryTM teams, we continue to break new grounds in antibody research, translational and precision medicine, and data sciences.

Staying true to our history, patients continue to guide every decision we make. Each and every one of us, regardless of where we sit in the organization is driven by our core purposes – that our unstoppable team will improve the lives of patients through innovative and differentiated antibody therapeutics.​

Today, we are proud to be building on this legacy, as we evolve into a fully integrated biotech innovation powerhouse.

Genmab CEO Jan van de Winkel reflects on 25 years of innovation in cancer treatment.

A history of accomplishments rooted in science

See our key accomplishments and moments

Our history has been powered by a dedication to antibody-based therapeutics. It is this same spirit that will guide us into the future.

You are now leaving to go to our collaborator’s website. If you continue, we encourage you to read the website’s privacy and cookie policy.